Sotagliflozin (CAS 1018899-04-1)

Application and positioning

Sotagliflozin is a dual SGLT1/SGLT2 inhibitor supplied as the free base. It is used in oral tablets for type 2 diabetes and for heart failure, with both intestinal and renal glucose transport targets. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Alogliptin benzoate (CAS 850649-62-6)
• Dapagliflozin (CAS 461432-26-8)
• Empagliflozin (CAS 864070-44-0)
• Ertugliflozin L-Pyroglutamic Acid (CAS 1210344-83-4)
• Methyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-alpha-D-xylo-hexopyranoside (CAS 1528636-39-6)
• 1-Chloro-2-[(4-ethoxyphenyl)methyl]-4-iodobenzene (CAS 1103738-29-9)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.